Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943959 | 0.93 | HDAC6 (0.72) | CRBNHDAC8HDAC6MKNK1MKNK2 | |
| SCHEMBL13702375 | 0.92 | HDAC8 (0.68) | CRBNHDAC8HDAC6CYP17A1CYP3A4 | |
| SCHEMBL12168604 | 0.91 | EPHX2 (0.60) | CRBNHDAC8HDAC6CTDSP1POLB | |
| SCHEMBL723332 | 0.91 | HDAC8 (0.70) | CRBNHDAC8HDAC6CTDSP1POLB | |
| SCHEMBL3617485 | 0.90 | CRBN (0.56) | CRBNHDAC8HDAC6MKNK1MKNK2 | |
| SCHEMBL14507774 | 0.90 | PLAU (0.54) | CRBNHDAC8HDAC6MKNK1MKNK2 | |
| SCHEMBL14210412 | 0.89 | CRBN (0.58) | CRBNHDAC8HDAC6CTDSP1POLB | |
| SCHEMBL15638622 | 0.89 | MEN1 (0.62) | CRBNHDAC8HDAC6CTDSP1POLB | |
| SCHEMBL13702395 | 0.89 | AOC3 (0.54) | CRBNHDAC8HDAC6MKNK1MKNK2 | |
| SCHEMBL13701675 | 0.89 | CRBN (0.52) | CRBNHDAC8HDAC6MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119907-A1 | Targeted Therapeutics | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| WO-1996012489-A1 | BICYCLIC NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119907-A1 | Targeted Therapeutics | ANXA3, ANXA5, ANXA6 | CRBN 1184/4885HDAC8 2227/4885HDAC6 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.